Camp4 Therapeutics Corporation
CAMP
$2.05
$0.063.02%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 652.00K | 0.00 | 350.00K | 350.00K | 350.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 652.00K | 0.00 | 350.00K | 350.00K | 350.00K |
| Cost of Revenue | 38.83M | 39.49M | 39.61M | 40.11M | 40.62M |
| Gross Profit | -38.18M | -39.49M | -39.26M | -39.76M | -40.27M |
| SG&A Expenses | 14.91M | 13.04M | 12.09M | 11.85M | 11.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.74M | 52.53M | 51.70M | 51.97M | 52.23M |
| Operating Income | -53.09M | -52.53M | -51.35M | -51.62M | -51.88M |
| Income Before Tax | -51.79M | -51.50M | -49.71M | -49.50M | -49.29M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -51.79 | -51.50 | -49.71 | -49.50 | -49.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.79M | -51.50M | -49.71M | -49.50M | -49.29M |
| EBIT | -53.09M | -52.53M | -51.35M | -51.62M | -51.88M |
| EBITDA | -51.39M | -50.82M | -49.63M | -49.91M | -50.20M |
| EPS Basic | -77.52 | -107.03 | -112.05 | -118.57 | -125.09 |
| Normalized Basic EPS | -48.45 | -66.90 | -70.03 | -74.11 | -78.18 |
| EPS Diluted | -77.52 | -107.03 | -112.05 | -118.57 | -125.09 |
| Normalized Diluted EPS | -48.45 | -66.90 | -70.03 | -74.11 | -78.18 |
| Average Basic Shares Outstanding | 18.76M | 1.94M | 1.78M | 1.68M | 1.58M |
| Average Diluted Shares Outstanding | 18.76M | 1.94M | 1.78M | 1.68M | 1.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |